Embracing Innovation and Identifying Emerging Trends: The 11th China Healthcare Industry Investment & M&A CEO Summit Concludes Successfully!
On September 2, the 2022 CHC·CITIC Securities Healthcare Conference and the 11th China Healthcare Industry Investment and M&A CEO Summit (hereinafter referred to as the “CEO Summit”) continued with remarkable sessions. In the main forum and two sub-forums themed “Healthcare Ecosystem” and “Innovative Healthcare,” leading experts from the healthcare industry, investment sector, and other relevant fields shared their insights and explorations on the current development status and future trends of the healthcare industry through keynote speeches and panel discussions, offering attendees further food for thought.
- Highlights from the Summit -
Wang Xin, Global Partner and President of Greater China at Frost & Sullivan, in the report "Future Trends in China's Healthcare Industry"，By comparing data from the primary and secondary capital markets in the healthcare sectors of China and the United States, this analysis provides a profound elucidation of the future trends in the development of China’s healthcare industry. It posits that there will be a continuous emergence of innovative enterprises in the biopharmaceutical and medical device sectors in China.
Wang Xin, Global Partner and President of Greater China at Frost & Sullivan
Chen Zhu, Chief Healthcare Industry Analyst at CITIC Securities,“Seeking Growth Certainty Amid the Rebalancing of the New Mechanism: Proactively Positioning in the Industry’s Hidden Champions” provides a comprehensive analysis through policy adjustments and the localization and self-reliance of the pharmaceutical industry.
Chen Zhu, Chief Healthcare Industry Analyst at CITIC Securities
Shi Yonghui, Executive Director and Senior Vice President of MicroTech Medical, delivered a presentation titled “Technology First, Broad Market: Pioneering and Advancing in Diabetes Management.”Starting from the pathogenesis of diabetes and the concepts of diagnosis and treatment, this article emphasizes the importance of blood glucose management, analyzes the technical advantages and market size of continuous glucose monitoring (CGM), and shares the innovative trends in diabetes management devices.
Shi Yonghui, Executive Director and Senior Vice President of MicroTech Medical
Investment Forum: Investment Logic in Healthcare Sectors Under the New Policies of the 14th Five-Year Plan, Moderated by Nie Hongxin, Managing Partner of Shanlan CapitalDuring the themed roundtable discussion, five seasoned investors—Wu Aimin, Founding Managing Partner of Jianyi Capital; Hu Hui, Founding Partner of Dingxin Capital; Zhao Chunsheng, Deputy General Manager of Investment at Autek China; and Sun Bo, Executive Director of General Investment Company—drew upon their own healthcare investment practices to explore the evolving landscape of healthcare investment in the new era, including hidden opportunities and challenges, as well as the resulting investment logic and strategies.
Moderator: Nie Hongxin, Managing Partner of Shanlan Capital
Guest Speakers: Wu Aimin, Founding Managing Partner of Jianyi Capital; Hu Hui, Founding Partner of Dingxin Capital; Zhao Chunsheng, Deputy General Manager of Investment at Autek China; Sun Bo, Executive Director of General Investment Company
“The Era of Innovative Medical Devices: The Path for Enterprise Development in the Context of Healthcare Reform,” Moderated by Liu Haitao, Director at Legend CapitalDuring the themed roundtable discussion, Sun Baolei, Director and Vice President of Terumo (China) Investment Co., Ltd., and Zhou Yinghua, Founding Managing Partner of Hanyi Capital, two healthcare investors, along with Shi Yonghui, Executive Director and Senior Vice President of MicroTech Medical, and Wang Hai, Vice President of Puchuang Medical, two medical device entrepreneurs, shared their insights on technological innovation in the medical device industry from the respective perspectives of capital and enterprise. They also provided an in-depth analysis of national policies, particularly the impact of healthcare reform policies on innovation in the medical device sector.
Moderator: Liu Haitao, Director at Legend Capital
Panelists: Sun Baolei, Director and Vice President of Terumo (China) Investment Co., Ltd.; Shi Yonghui, Executive Director and Senior Vice President of MicroTech Medical; Zhou Yinghua, Founding Managing Partner of Hanyi Capital; Wang Hai, Vice President of Puchuang Medical
In the afternoon, presented simultaneously“Healthcare Ecosystem” and “Innovative Healthcare”At the two major sub-forums, industry experts and healthcare investors from specialized sectors including CROs, biological raw materials, brain science, AI-driven healthcare, and consumer healthcare
People gathered together to share perspectives, exchange insights, and identify trends, offering a wealth of valuable content in a vibrant and engaging atmosphere.
The CEO Summit, featuring two days of exchanges and intellectual engagement, has concluded successfully. Marking its eleventh consecutive year without absence, the CEO Summit has established a platform for multi-party collaboration and co-creation among stakeholders in the healthcare industry, investment, scientific research, and industrial parks, contributing to the advancement of China’s healthcare sector.Quantity.
Following the conference, attendees expressed that they had gained valuable insights and voiced strong anticipation for the 12th China Healthcare Industry Investment and M&A CEO Summit next year, hoping it will bring forth further exploration and discoveries in China’s healthcare sector.
Follow the “CHC Healthcare Media” WeChat official account and reply with “2022 CEO Summit” to view more highlights from the summit.
-END-